Hsp60 as a Novel Target in IBD Management: A Prospect

Giuseppe Bonaventura, Marie Noel Zeenny, Francesco Carini, Francesco Cappello, Angelo Leone, Giovanni Tomasello, Fabio Bucchieri, Rosalyn Jurjus, Marie-Noel Zeenny, Abdo Jurjus, Everly Conway De Macario, Francesco Cappello, Alberto J.L. Macario

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Inflammatory bowel disease (IBD) encompasses various pathological conditions similar but distinct that share a multifactorial etiology, including involvement of the intestinal barrier function, the immune system, and intestinal microorganisms. Hsp60 is a chaperonin component of the chaperoning system, present in all cells and tissues, including the intestine. It plays important roles in cell physiology outside and inside mitochondria, its canonical place of residence. However, Hsp60 can also be pathogenic in many conditions, the Hsp60 chaperonopathies, possibly including IBD. The various clinico-pathological types of IBD have a complicated mix of causative factors, among which Hsp60 can be considered a putatively important driver of events and could play an etiopathogenic role. This possibility is discussed in this review. We also indicate that Hsp60 can be a biomarker useful in disease diagnosing and monitoring and, if found active in pathogenesis, should become a target for developing new therapies. The latter are particularly needed to alleviate patient suffering and to prevent complications, including colon cancer.
Original languageEnglish
Pages (from-to)26-
Number of pages8
JournalFrontiers in Pharmacology
Volume10
Publication statusPublished - 2019

Fingerprint

Disease Management
Inflammatory Bowel Diseases
Chaperonins
Cell Physiological Phenomena
Psychological Stress
Colonic Neoplasms
Intestines
Immune System
Mitochondria
Biomarkers
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Cite this

Hsp60 as a Novel Target in IBD Management: A Prospect. / Bonaventura, Giuseppe; Zeenny, Marie Noel; Carini, Francesco; Cappello, Francesco; Leone, Angelo; Tomasello, Giovanni; Bucchieri, Fabio; Jurjus, Rosalyn; Zeenny, Marie-Noel; Jurjus, Abdo; De Macario, Everly Conway; Cappello, Francesco; Macario, Alberto J.L.

In: Frontiers in Pharmacology, Vol. 10, 2019, p. 26-.

Research output: Contribution to journalArticle

Bonaventura, Giuseppe ; Zeenny, Marie Noel ; Carini, Francesco ; Cappello, Francesco ; Leone, Angelo ; Tomasello, Giovanni ; Bucchieri, Fabio ; Jurjus, Rosalyn ; Zeenny, Marie-Noel ; Jurjus, Abdo ; De Macario, Everly Conway ; Cappello, Francesco ; Macario, Alberto J.L. / Hsp60 as a Novel Target in IBD Management: A Prospect. In: Frontiers in Pharmacology. 2019 ; Vol. 10. pp. 26-.
@article{8469d5dc980d4ef5b77a7a9119545538,
title = "Hsp60 as a Novel Target in IBD Management: A Prospect",
abstract = "Inflammatory bowel disease (IBD) encompasses various pathological conditions similar but distinct that share a multifactorial etiology, including involvement of the intestinal barrier function, the immune system, and intestinal microorganisms. Hsp60 is a chaperonin component of the chaperoning system, present in all cells and tissues, including the intestine. It plays important roles in cell physiology outside and inside mitochondria, its canonical place of residence. However, Hsp60 can also be pathogenic in many conditions, the Hsp60 chaperonopathies, possibly including IBD. The various clinico-pathological types of IBD have a complicated mix of causative factors, among which Hsp60 can be considered a putatively important driver of events and could play an etiopathogenic role. This possibility is discussed in this review. We also indicate that Hsp60 can be a biomarker useful in disease diagnosing and monitoring and, if found active in pathogenesis, should become a target for developing new therapies. The latter are particularly needed to alleviate patient suffering and to prevent complications, including colon cancer.",
keywords = "Hsp60, chaperoning system, chaperonopathy, chaperonotherapy, immune system, inflammatory bowel disease, intestinal wall, microbiota",
author = "Giuseppe Bonaventura and Zeenny, {Marie Noel} and Francesco Carini and Francesco Cappello and Angelo Leone and Giovanni Tomasello and Fabio Bucchieri and Rosalyn Jurjus and Marie-Noel Zeenny and Abdo Jurjus and {De Macario}, {Everly Conway} and Francesco Cappello and Macario, {Alberto J.L.}",
year = "2019",
language = "English",
volume = "10",
pages = "26--",
journal = "Frontiers in Pharmacology",
issn = "1663-9812",
publisher = "Frontiers Media S. A.",

}

TY - JOUR

T1 - Hsp60 as a Novel Target in IBD Management: A Prospect

AU - Bonaventura, Giuseppe

AU - Zeenny, Marie Noel

AU - Carini, Francesco

AU - Cappello, Francesco

AU - Leone, Angelo

AU - Tomasello, Giovanni

AU - Bucchieri, Fabio

AU - Jurjus, Rosalyn

AU - Zeenny, Marie-Noel

AU - Jurjus, Abdo

AU - De Macario, Everly Conway

AU - Cappello, Francesco

AU - Macario, Alberto J.L.

PY - 2019

Y1 - 2019

N2 - Inflammatory bowel disease (IBD) encompasses various pathological conditions similar but distinct that share a multifactorial etiology, including involvement of the intestinal barrier function, the immune system, and intestinal microorganisms. Hsp60 is a chaperonin component of the chaperoning system, present in all cells and tissues, including the intestine. It plays important roles in cell physiology outside and inside mitochondria, its canonical place of residence. However, Hsp60 can also be pathogenic in many conditions, the Hsp60 chaperonopathies, possibly including IBD. The various clinico-pathological types of IBD have a complicated mix of causative factors, among which Hsp60 can be considered a putatively important driver of events and could play an etiopathogenic role. This possibility is discussed in this review. We also indicate that Hsp60 can be a biomarker useful in disease diagnosing and monitoring and, if found active in pathogenesis, should become a target for developing new therapies. The latter are particularly needed to alleviate patient suffering and to prevent complications, including colon cancer.

AB - Inflammatory bowel disease (IBD) encompasses various pathological conditions similar but distinct that share a multifactorial etiology, including involvement of the intestinal barrier function, the immune system, and intestinal microorganisms. Hsp60 is a chaperonin component of the chaperoning system, present in all cells and tissues, including the intestine. It plays important roles in cell physiology outside and inside mitochondria, its canonical place of residence. However, Hsp60 can also be pathogenic in many conditions, the Hsp60 chaperonopathies, possibly including IBD. The various clinico-pathological types of IBD have a complicated mix of causative factors, among which Hsp60 can be considered a putatively important driver of events and could play an etiopathogenic role. This possibility is discussed in this review. We also indicate that Hsp60 can be a biomarker useful in disease diagnosing and monitoring and, if found active in pathogenesis, should become a target for developing new therapies. The latter are particularly needed to alleviate patient suffering and to prevent complications, including colon cancer.

KW - Hsp60

KW - chaperoning system

KW - chaperonopathy

KW - chaperonotherapy

KW - immune system

KW - inflammatory bowel disease

KW - intestinal wall

KW - microbiota

UR - http://hdl.handle.net/10447/350681

M3 - Article

VL - 10

SP - 26-

JO - Frontiers in Pharmacology

JF - Frontiers in Pharmacology

SN - 1663-9812

ER -